Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - PTC Therapeutics (NASDAQ:PTCT)

PTC's Huntington study was positive. Why did its stock fall?

A potentially pivotal trial PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is a progressive neurodegenerative disorder caused by mutation of the huntingtin (HTT) gene, leading to the breakdown of brain cells. It is characterized by uncontrolled movements (chorea), cognitive decline, and psychiatric disturbances. The study me…

PTC's Huntington’s study succeeds, but accelerated approval uncertain

PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study, but stopped short of spelling out the important data that could help speed the drug to market.